Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Rectal Neoplasms 2Neoplasms 2Waldenstrom Macroglobulinemia 1Prostatic Neoplasms 1Paraproteinemias 1Lung Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Rituximab 99Cyclophosphamide 63fludarabine phosphate 54Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 33Bortezomib 33Whole-Body Irradiation 32ibrutinib 29Dexamethasone 27Tacrolimus 25Cyclosporine 25Etoposide 22Busulfan 22Melphalan 20Filgrastim 20Methotrexate 18Lenalidomide 18Antilymphocyte Serum 18Radiotherapy 16zanubrutinib 14Bendamustine Hydrochloride 14Sirolimus 13Calcium Dobesilate 11Everolimus 10venetoclax 9ibritumomab tiuxetan 9Prednisone 9Cyclosporins 9idelalisib 8Indium 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Waldenstrom Macroglobulinemia × Rifaximin × Clear all
NCT03820817 2026-05-26

Rifaximin in Patients With Monoclonal Gammopathy

Emory University

Phase 1 Completed
50 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡